关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300981 证券简称：中红医疗 公告编号：2026-007 中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十 六次会议拟定于 2026 年 2 月 5 日（星期四）召开 2026 年第一次临时股东会， 会议有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议时间： （1）现场会议时间：2026年2月5日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年2月5日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为20 ...

证券代码：300981 证券简称：中红医疗 公告编号：2026-003 中红普林医疗用品股份有限公司 第四届董事会第十六次会议决议公告 一、会议召开情况 中红普林医疗用品股份有限公司（以下简称"公司"）第四届董事会第十六 次会议于 2026 年 1 月 19 日以通讯方式召开，2026 年 1 月 16 日公司以电话和电 子邮件方式向全体董事发出会议通知（全体董事已同意豁免本次临时董事会通知 的时间要求）。会议应出席董事 9 人，实际出席董事 9 人。会议由董事长桑树军 先生主持，公司高级管理人员和相关人员列席了会议。会议的召集、召开符合相 关法律、法规和《公司章程》的规定。 二、会议审议情况 1. 审议通过《关于 2026 年度拟使用自有闲置资金投资低风险型理财产品 的议案》 公司在保障其正常经营和资金安全的前提下，使用不超过人民币 20 亿元的 自有资金购买安全性高、流动性好、稳健型、风险可控的低风险理财产品，在上 述额度内，资金可以滚动循环使用。本次投资事项有效期限为 2026 年度，自公 司 2026 年第一次临时股东会审议通过后生效。同时，董事会提请 2026 年第一次 临时股东会授权董事长、总经理 ...

Core Viewpoint - The company has completed the cancellation of a portion of its initial public offering fundraising account, with a net fundraising amount of 799 million yuan in September 2023 [1] Group 1: Fundraising and Financial Management - The company raised a net amount of 799 million yuan in September 2023 [1] - Due to business development, the company plans to optimize the "Shanghai Carbon Fiber Polyether Ether Ketone Composite Material R&D Center Project" in 2024, with a completion date set for December 2025 [1] - The remaining funds from the project will be permanently allocated to supplement working capital [1] Group 2: Account and Regulatory Changes - The company has transferred the remaining project funds to its own account, leading to the cancellation of the dedicated fundraising account at the Bank of China, Minhang Branch in Shanghai [1] - Corresponding regulatory agreements related to the dedicated account have also been terminated [1]

Trading Information Summary - On January 14, 2026, Zhonghong Medical (300981) closed at 13.61 yuan, up 0.15%, with a turnover rate of 2.27%, trading volume of 89,400 shares, and a transaction amount of 1.23 billion yuan [1] - On the same day, the net outflow of main funds was 1.97 million yuan, while the net inflow of speculative funds was 9.83 million yuan, and the net outflow of retail funds was 7.86 million yuan [2] Company Announcement Summary - Zhonghong Medical announced a change in the signing registered accountants for the 2025 audit, with Chen Yongjun added as a signing accountant. The previous signing accountants were Zhang Huiling, Wu Lili, and He Houquan [1][2] - The change in accountants has been orderly transitioned and will not affect the financial statement audit and internal control audit for the year 2025 [1]

Group 1 - The company Zhonghong Medical announced a change in its signing registered accountants to Zhang Huiling, He Houquan, and Chen Yongjun [2]

证券代码：300981 证券简称：中红医疗 公告编号：2026-002 中红普林医疗用品股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日、2025 年 9 月 15 日召开第四届董事会第十一次（定期）会议、2025 年第三次 临时股东大会，审议通过了《关于续聘 2025 年度审计机构的议案》，同意续聘 容诚会计师事务所（特殊普通合伙）（以下简称"容诚会计师事务所"）为公司 2025 年度审计机构，具体内容详见公司于 2025 年 8 月 27 日在巨潮资讯网披露 的《关于续聘 2025 年度审计机构的公告》（公告编号：2025-074）。 四、备查文件 1. 容诚会计师事务所出具的《关于变更签字注册会计师的函》。 特此公告 中红普林医疗用品股份有限公司 近日，公司收到容诚会计师事务所出具的《关于变更签字注册会计师的函》， 现将具体情况公告如下： 一、本次变更签字注册会计师的情况 容诚会计师事务所作为公司 2025 年年度报告和内部控制审 ...

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

证券代码：300981 证券简称：中红医疗 公告编号：2026-001 中红普林医疗用品股份有限公司 关于子公司参与集中带量采购项目拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 中红普林医疗用品股份有限公司（以下简称"公司"）控股子公司江西科伦 医疗器械制造有限公司（以下简称"科伦医械"）于近期参加省际联盟缝合线等 5 类医用耗材集中带量采购项目的投标工作。根据省际联盟缝合线等 5 类医用耗 材集中带量采购中选结果公告显示，科伦医械部分产品拟中选上述集中带量采购 项目。现将相关情况公告如下： | 血糖管（氟化钠／肝 | | --- | | 素钠）、血清管（分 | | 离胶）、血沉管（枸 | | 橼酸钠 1：4） | | 3ml PPT 管（分离 | | 胶／ EDTAK2）、 | | 肝素管（分离 | | 胶/肝素锂）、 | | 肝素管（分离 | | 胶/肝素钠）、 | | 血清管（分离 | | 胶/促凝剂）、 | | EDTAK2 管、 | | EDTAK3 管、 | | EDTANa2 管、 | | PT 管（枸橼酸 | | 钠 1：9）、 ...

Core Viewpoint - Zhonghong Medical has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, including nitrile and PVC gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. - As of September 30, 2025, Zhonghong Medical reported a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. Group 2: Market Position and Strategy - The company primarily focuses on export sales through an ODM direct sales model, where it designs and produces medical devices and consumables for overseas brand owners [3]. - As of the 2024 annual report, overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. - Zhonghong Medical is classified as a state-owned enterprise, with the ultimate control held by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. Group 3: Product Development and Innovation - The company is collaborating with Guilin University of Technology to develop a multi-layer nuclear radiation protective glove, which includes a chemical protective layer, a white warning layer, and a nuclear radiation protective layer [2]. - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing various infusion modes and safety features [2].

Core Insights - The article emphasizes the importance of technological innovation in the medical health and protection sector, highlighting how 中红医疗's subsidiary, 桂林恒保健康防护有限公司 (中红恒保), is leading the latex products industry in China through groundbreaking research and development [1] Group 1: Industry Challenges - Traditional medical gloves and condoms primarily rely on natural rubber latex, which, while elastic and cost-effective, poses two significant industry challenges: the potential for allergic reactions due to latex proteins and inadequate skin comfort, which fails to meet the high demands of precise medical operations and intimate scenarios [2] Group 2: Technological Breakthroughs - 中红恒保's self-developed third-generation polyisoprene (PI) material addresses these challenges with a revolutionary solution, offering high elasticity, a high friction coefficient, and resistance to acid and alkali corrosion. The material provides a second-skin feel, eliminating the "foreign body" sensation during use, and is designed for both surgical and intimate health applications [3] - The PI material ensures zero allergy risk by completely removing allergenic proteins found in natural latex and avoiding harmful substances like formaldehyde and nitrosamines during production, making it particularly suitable for healthcare workers and sensitive individuals [3] - The PI surgical gloves exhibit significantly enhanced puncture resistance, reducing the risk of cross-infection during surgeries, and the product line includes the "麦迪斯®聚异戊二烯外科手套" for clinical protection and "倍力乐PI安全套" for intimate health [3] Group 3: Technological Foundation - 中红恒保's technological advancements are rooted in years of experience in the latex field, supported by its status as a national high-tech enterprise and a recognized "little giant" in specialized innovation. The company prioritizes technological innovation as a strategic core, aiming to become a global manufacturing center for latex products [4] - The company holds multiple proprietary innovations and core technology patents, establishing a leading advantage in new material research and production, which is reflected in the manufacturing processes of its PI medical gloves and condoms [4] - 中红恒保 collaborates with universities for continuous innovation in key areas like protective materials, focusing on cutting-edge, intelligent, and green research directions to overcome industry technical bottlenecks and expand its global market presence [4]